Ayala Pharmaceuticals
Manufacturing · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4 Oppenheimer St, Rehovot, Central Distr...Phone Number
+972 83731541Website
www.ayalapharma.comRevenue
<$5 MillionStock Symbol
ADXSIndustry
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.Explore more
Ayala Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Ayala Pharmaceuticals Tech Stack
A closer look at the technologies used by Ayala Pharmaceuticals
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Ayala Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical... Read More
